DoubleLine ETF Adviser’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,209
Closed -$754K – 218
2026
Q2
$754K Sell
1,209
-107
-8% -$72.8K 0.31% 87
2026
Q1
$1.02M Buy
+1,316
New +$1.01M 0.39% 68

Other funds holding REGN

DoubleLine ETF Adviser's REGN Position: Q3 2026 in Review

DoubleLine ETF Adviser sold out of Regeneron Pharmaceuticals (REGN) in Q3 2026, closing a stake of 1,209 shares — an estimated $754K sold.

DoubleLine ETF Adviser first reported a position in REGN in Q1 2026 and held it in 2 quarters. The position peaked at $1.02M in Q1 2026. 1,423 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • DoubleLine ETF Adviser reported no remaining Regeneron Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • DoubleLine ETF Adviser sold 1,209 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $754K.
  • DoubleLine ETF Adviser first reported a position in Regeneron Pharmaceuticals in Q1 2026 and held it in 2 quarters.
  • DoubleLine ETF Adviser's Regeneron Pharmaceuticals position peaked at $1.02M in Q1 2026.
  • 1,423 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on DoubleLine ETF Adviser's 13F filing for Q3 2026, filed 13 Nov 2026.